These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 26394771)

  • 1. Risk-adapted strategies for the treatment of Hodgkin lymphoma.
    Keller J; Carson KR
    Expert Opin Drug Saf; 2015 Oct; 14(10):1519-30. PubMed ID: 26394771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma.
    Watkins MP; Fanale MA; Bartlett NL
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):81-90. PubMed ID: 29366607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
    Kostakoglu L; Evens AM
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):20-35. PubMed ID: 25000313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives.
    Eichenauer DA; Böll B; Diehl V
    Expert Opin Pharmacother; 2014 Jun; 15(8):1139-51. PubMed ID: 24749840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
    Hutchings M
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.
    Romano A; Parrinello NL; Vetro C; Forte S; Chiarenza A; Figuera A; Motta G; Palumbo GA; Ippolito M; Consoli U; Di Raimondo F
    Br J Haematol; 2015 Mar; 168(5):689-700. PubMed ID: 25376846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of newly diagnosed advanced stage Hodgkin lymphoma.
    Uhm J; Kuruvilla J
    Blood Rev; 2012 Jul; 26(4):167-74. PubMed ID: 22542250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
    Cochrane T; Campbell BA; Gangatharan SA; Latimer M; Khor R; Christie DRH; Gilbertson M; Ratnasingam S; Palfreyman E; Lee HP; Trotman J; Hertzberg M; Dickinson M
    Intern Med J; 2021 Dec; 51(12):2119-2128. PubMed ID: 34505342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Gentzler RD; Evens AM; Rademaker AW; Weitner BB; Mittal BB; Dillehay GL; Petrich AM; Altman JK; Frankfurt O; Variakojis D; Singhal S; Mehta J; Williams S; Kaminer L; Gordon LI; Winter JN
    Br J Haematol; 2014 Jun; 165(6):793-800. PubMed ID: 24628515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival.
    Sucak GT; Özkurt ZN; Suyani E; Yaşar DG; Akdemir ÖÜ; Aki Z; Yeğin ZA; Yağci M; Kapucu ÖL
    Ann Hematol; 2011 Nov; 90(11):1329-36. PubMed ID: 21437590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hodgkin lymphoma.
    Gobbi PG; Ferreri AJ; Ponzoni M; Levis A
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):216-37. PubMed ID: 22867814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modern treatment of Hodgkin lymphoma.
    Bartlett NL
    Curr Opin Hematol; 2008 Jul; 15(4):408-14. PubMed ID: 18536581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hodgkin's lymphoma therapy: past, present, and future.
    Rathore B; Kadin ME
    Expert Opin Pharmacother; 2010 Dec; 11(17):2891-906. PubMed ID: 21050034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents.
    Giulino-Roth L; Keller FG; Hodgson DC; Kelly KM
    Br J Haematol; 2015 Jun; 169(5):647-60. PubMed ID: 25824371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
    Zhao J; Qiao W; Wang C; Wang T; Xing Y
    Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on disease biomarkers for Hodgkin lymphoma.
    Cirillo M; Borchmann S
    Expert Rev Hematol; 2020 May; 13(5):481-488. PubMed ID: 32193957
    [No Abstract]   [Full Text] [Related]  

  • 17. Progress in the initial management of Hodgkin's Lymphoma.
    Marri PR; Ansell SM
    Transfus Apher Sci; 2013 Aug; 49(1):12-8. PubMed ID: 23769695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of PET in first-line treatment of Hodgkin lymphoma.
    Trotman J; Barrington SF
    Lancet Haematol; 2021 Jan; 8(1):e67-e79. PubMed ID: 33357485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hodgkin lymphoma in Tyrol-a population-based study.
    Fong D; Steurer M; Greil R; Gunsilius E; Spizzo G; Gastl G; Tzankov A
    Ann Hematol; 2009 May; 88(5):449-56. PubMed ID: 18846373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management.
    Ansell SM
    Am J Hematol; 2014 Jul; 89(7):771-9. PubMed ID: 24953862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.